Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 34143970

Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2021 Jul
First author
Pujade-Lauraine E

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2021 Jul;22(7):903-905. doi: 10.1016/S1470-2045(21)00303-X.
    note
    Source null
    related pmid
    34143972
    relationship
    Comment in

Authors and identifiers

  1. name
    Pujade-Lauraine E
    type
    Author
  2. name
    Fujiwara K
    type
    Author
  3. name
    Ledermann JA
    type
    Author
  4. name
    Oza AM
    type
    Author
  5. name
    Kristeleit R
    type
    Author
  6. name
    Ray-Coquard IL
    type
    Author
  7. name
    Richardson GE
    type
    Author
  8. name
    Sessa C
    type
    Author
  9. name
    Yonemori K
    type
    Author
  10. name
    Banerjee S
    type
    Author
  11. name
    Leary A
    type
    Author
  12. name
    Tinker AV
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Pujade-Lauraine E
    type
    Author
  2. name
    Fujiwara K
    type
    Author
  3. name
    Ledermann JA
    type
    Author
  4. name
    Oza AM
    type
    Author
  5. name
    Kristeleit R
    type
    Author
  6. name
    Ray-Coquard IL
    type
    Author
  7. name
    Richardson GE
    type
    Author
  8. name
    Sessa C
    type
    Author
  9. name
    Yonemori K
    type
    Author
  10. name
    Banerjee S
    type
    Author
  11. name
    Leary A
    type
    Author
  12. name
    Tinker AV
    type
    Author
bibliography ids
  1. nci-bib-c94969399d5c255af17199ab
book metadata
content sha256
2b11eebae859973aa854df19786b10a7b101d4a07616296404c9162d0b0bcb44
document type
citation
dois
  1. 10.1016/S1470-2045(21)00216-3
electronic publication date
display
2021 Jun 15
precision
day
year
2021
evidence scope
bibliographic_metadata_only
id
pubmed:34143970
immutable id
pubmed:34143970@2b11eebae859973aa854df19786b10a7b101d4a07616296404c9162d0b0bcb44
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
7
name
The Lancet. Oncology
nlm unique id
100957246
pages
1034-1046
volume
22
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2021 Jul;22(7):903-905. doi: 10.1016/S1470-2045(21)00303-X.
    note
    Source null
    related pmid
    34143972
    relationship
    Comment in
outcomes validated
false
pmid
34143970
provenance
batch id
192b6392c165c6b06274
provider
NCBI PubMed ESummary
record sha256
d2a94eda43ca8c256c7ce737906e93e5a57e53f4a26460fea49c6269d7aff908
response sha256
7d81e9fb11ee99e6ad4116aecd61ba71cd6bf76f2a8f8f6d15c5c85e9c6c56b4
retrieved at
2026-09-09T23:48:02.713075+00:00
publication date
display
2021 Jul
precision
month
year
2021
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Multicenter Study
  4. Randomized Controlled Trial
  5. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/34143970/
title
Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study.

Preserved source evidence · Not medical advice